Four months into commercialization and $5.6 million in net revenue sounds like momentum — until you notice that Citius Oncology is burning through cash fast enough that it entered May 2026 with $2.6 million on hand before scrambling to close a $36.5 million debt-and-equity package just to finish hiring its own sales force. That sequencing problem — launching a specialty oncology drug before the commercial infrastructure exists to sell it — defines everything about where LYMPHIR stands right now.
The market access story is genuinely strong. Near-100% covered commercial lives, zero reimbursement denials, and 83% of target accounts on formulary or in active review within four months is not typical for a newly launched specialty infusible. An 80% gross margin on a biologics-class product reinforces the unit economics. But $1.7 million in Q2 net revenue against $23.6 million in G&A expenses for the same period tells the real story: Citius is spending roughly fourteen dollars to generate one dollar of product revenue. The full sales force won’t be deployed until mid-summer, which means the company effectively launched commercially incomplete, relied on initial distributor channel fill to pad the headline number, and then needed emergency financing to reach full operating capacity.
The $25 million Avenue Capital term loan is milestone-gated — $10 million now, $7 million unlocked October 1 contingent on revenue and liquidity thresholds, $8 million more contingent on additional revenue milestones in January 2027. That structure is a creditor betting on execution, not a vote of confidence. If community infusion center penetration — the stated next commercial phase — lags, those October milestones become a pressure point, not a resource. Europe via Named Patient Programs adds optionality but no near-term revenue scale. The Phase 1 combination data with pembrolizumab and in the CAR-T conditioning setting are scientifically interesting for LYMPHIR’s Treg depletion mechanism, but they are years from mattering commercially.
The single number to watch is Q3 net revenue when reported in August — specifically whether it clears $3 million, which would signal that the transition from channel fill to genuine treatment-driven demand is real rather than a restock artifact. Anything below that threshold makes the October loan tranche a genuine cliff.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
